miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN

Gong,Li; Zhang,Weimin; Yuan,Yuchao; Xing,Xia; Li,Hui; Zhao,Guifeng

doi:10.3892/ol.2018.8743

miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN

Authors:
- Li Gong
- Weimin Zhang
- Yuchao Yuan
- Xia Xing
- Hui Li
- Guifeng Zhao
View Affiliations

Affiliations: Department of Gynaecology, People's Hospital of Rizhao, Rizhao, Shandong 276826, P.R. China, Department of Obstetrics and Gynecology, Zhangqiu Maternal and Child Health Care Hospital, Jinan, Shandong 250000, P.R. China, Department of Obstetrics and Gynecology, People's Hospital of Zhangqiu, Jinan, Shandong 250200, P.R. China, Department of Rehabiliation Medicine, People's Hospital of Zhangqiu, Jinan, Shandong 250200, P.R. China, Department of Surgery, People's Hospital of Weifang, Weifang, Shandong 261000, P.R. China
Published online on: May 18, 2018 https://doi.org/10.3892/ol.2018.8743
Pages: 984-990

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian carcinoma is the most lethal of the gynecologic malignancies worldwide. Increasing evidence suggests dysfunction of microRNAs (miRNAs) plays an important role in human cancers. The function of miR-222 was detected in ovarian carcinoma to verify the regulation of phosphatase and tensin homolog (PTEN) by miR-222. miR-222 expression in ovarian carcinoma tissues and cell lines were examined using RT-qPCR. Transwell assay was used to detect miR-222 effects on ovarian carcinoma cell migration and invasion. Western blot analysis and luciferase assays were performed to validate PTEN as miR-222 targets. miR-222 expression was upregulated in ovarian carcinoma tissues and three cell lines (A2780, SKOV-3 and OVCAR-3). Ectopic overexpression of miR-222 in ovarian carcinoma cells was sufficient to promote invasion and migration. PTEN acted as a direct target of miR-222. Overexpression of PTEN inhibited human ovarian carcinoma cell migration and invasion. In summary, our findings suggest that miR-222 plays an important role in promoting ovarian carcinoma cell invasion and migration and miR-222/PTEN may be a novel therapeutic target of miRNA-mediated promotion of cell invasion and migration in ovarian carcinoma.

View Figures

View References

1	Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW and Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
2	Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, et al: Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 11:2556–2565. 2012. View Article : Google Scholar : PubMed/NCBI
3	Pal MK, Jaiswar SP, Dwivedi VN, Tripathi AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI
4	Lupia M and Cavallaro U: Ovarian cancer stem cells: Still an elusive entity? Mol Cancer. 16:642017. View Article : Google Scholar : PubMed/NCBI
5	Koutsaki M, Libra M, Spandidos DA and Zaravinos A: The miR-200 family in ovarian cancer. Oncotarget. 8:66629–66640. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Xu C, Wang Y and Zhang X: MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a. Am J Cancer Res. 7:1096–1106. 2017.PubMed/NCBI
7	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
8	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chan E, Prado DE and Weidhaas JB: Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends Mol Med. 17:235–243. 2011. View Article : Google Scholar : PubMed/NCBI
11	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hata A and Lieberman J: Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 8:re32015. View Article : Google Scholar : PubMed/NCBI
13	Saumet A and Lecellier CH: MicroRNAs and personalized medicine: Evaluating their potential as cancer biomarkers. Adv Exp Med Biol. 888:5–15. 2015. View Article : Google Scholar : PubMed/NCBI
14	Srivastava SK, Arora S, Averett C, Singh S and Singh AP: Modulation of microRNAs by phytochemicals in cancer: Underlying mechanisms and translational significance. BioMed Res Int. 2015:8487102015. View Article : Google Scholar : PubMed/NCBI
15	Virant-Klun I, Ståhlberg A, Kubista M and Skutella T: MicroRNAs: From female fertility, germ cells, and stem cells to cancer in humans. Stem Cells Int. 2016:39849372016. View Article : Google Scholar : PubMed/NCBI
16	Kinose Y, Sawada K, Nakamura K and Kimura T: The role of microRNAs in ovarian cancer. BioMed Res Int. 2014:2493932014. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Kim S and Kim IM: Regulation of metastasis by microRNAs in ovarian cancer. Front Oncol. 4:1432014. View Article : Google Scholar : PubMed/NCBI
18	Garofalo M, Quintavalle C, Romano G, Croce CM and Condorelli G: miR221/222 in cancer: Their role in tumor progression and response to therapy. Curr Mol Med. 12:27–33. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu Z, Ou-Yang S, Wu H, Zhong Z, Yin Z, et al: MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep. 4:75462014. View Article : Google Scholar : PubMed/NCBI
20	Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, et al: MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget. 7:80633–80654. 2016. View Article : Google Scholar : PubMed/NCBI
21	Li B, Lu Y, Wang H, Han X, Mao J, Li J, Yu L, Wang B, Fan S, Yu X, et al: miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomed Pharmacother. 79:93–101. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fang G, Liu J, Wang Q, Huang X, Yang R, Pang Y and Yang M: MicroRNA-223-3p regulates ovarian cancer cell proliferation and invasion by targeting SOX11 expression. Int J Mol Sci. 18(pii): E12082017. View Article : Google Scholar : PubMed/NCBI
23	Xu J, Jiang N, Shi H, Zhao S, Yao S and Shen H: miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1. Int J Oncol. 50:22362017. View Article : Google Scholar : PubMed/NCBI
24	Shen H, Wang D, Li L, Yang S, Chen X, Zhou S, Zhong S, Zhao J and Tang J: MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Gene. 596:110–118. 2017. View Article : Google Scholar : PubMed/NCBI
25	Wang DD, Yang SJ, Chen X, Shen HY, Luo LJ, Zhang XH, Zhong SL, Zhao JH and Tang JH: miR-222 induces adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway. Tumour Biol. 37:15315–15324. 2016. View Article : Google Scholar : PubMed/NCBI